Is Capmatinib launched in Taiwan?

As to whether capmatinib (Capmatinib) is marketed in Taiwan, you can check the official website of Taiwan's drug regulatory agency, health department or drug manufacturer, or consult a medical professional or pharmacist to obtain the latest listing status and related information. These channels provide the most accurate and up-to-date information on drug launches.

Capmatinib is an oral tyrosine kinase inhibitor that is a targeted therapy for specific cancers. It is mainly used to treat patients with advanced or metastatic non-small cell lung cancer (NSCLC) with overexpression of METprimary tyrosine kinase (METex14skipping mutations or METincrease).

The mechanism of action of capmatinib is to block its signal transduction pathway by specifically inhibiting the activity ofMETtyrosine kinase. MET is a receptor tyrosine kinase that participates in the regulation of biological processes such as cell growth, differentiation and migration in normal cells. However, in some cancer cells, MET is overexpressed or abnormally activated, leading to abnormal proliferation and metastasis of tumor cells. Capmatinib inhibits the activity of MET kinase, thereby inhibiting the growth and spread of tumor cells.

Capmatinib is not currently on the market in China, so patients cannot purchase it domestically. Capmatinib abroad is divided into original drugs and generic drugs. The original drug is mainly the original drug from Novartis, with a price of about 35,000 yuan and a specification of 200mg*60; the price of generic drugs is very cheap, mainly Laos generic drugs, with a price of about 3,000 to 4,000 yuan. The ingredients of original drugs and generic drugs are basically the same.